A retrospective study of concurrent radiotherapy plus S-1 for treating advanced non-small cell lung cancer. Issue 22 (June 2018)

• Record Type: Journal Article
• Authors: Zhao, Dejun; Feng, Jun-fei; Wang, Xue-hui
• Other Names: Chung. Fu-Tsai section editor.
• Is Part Of: Medicine. Volume 97:Issue 22(2018)
• Publication Date: 2018-06
• Subjects: cisplatin -- concurrent radiotherapy -- non-small-cell lung cancer -- S-1; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000010740
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: We investigated the efficacy of concurrent radiotherapy plus S-1 (CRS) for treating unresectable stage III advanced non-small-cell lung cancer (ANSCLC). Seventy five ANSCLC patients were included in this retrospective study. Of those, 40 patients were assigned to an intervention group, and received S-1 (orally at 40 mg/m 2 ) twice daily for 14 consecutive days. Then, concurrent radiotherapy was administered in 2 Gy fractions, 5 times weekly for a total dose of 60 Gy. The other 35 patients were assigned to a control group, and underwent concurrent radiotherapy (the same as the intervention group) and cisplatin (60 mg/m 2 on day 1 (CRC). The outcome measurements included overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and toxicity. The 3-year ORR was 60.7% and 43.9% for intervention group and control group, respectively ( P = .031). The median OS was 34.1 months and 25.3 months in the intervention and control groups, respectively ( P = .041). The median PFS was 31.5 months for intervention group, while it was 22.4 months for control group ( P = .048). No significant difference in toxicity was found between the 2 groups. The results demonstrated that the efficacy of CRS was superior to the CRC in ANSCLC patients with similar toxicity.